Suppr超能文献

复制 - 我们为什么需要发表研究结果。

Replication - why we need to publish our findings.

机构信息

Cardiovascular Division, King's College London, Rayne Institute, St Thomas' Hospital London, SE17EH, United Kingdom.

US FDA, Office of Clinical Pharmacology and Office of Translational Science Sci Silver Spring, MD 20903, USA.

出版信息

Pharmacol Res Perspect. 2015 Aug;3(4):e00164. doi: 10.1002/prp2.164. Epub 2015 Jul 24.

Abstract

The pharmacology research sector is changing to accommodate a need for greater transparency and better standards. The themed articles contained herein explain how Pharmacology Research and Perspectives (PR&P) has responded to this agenda. This issue of PR&P contains three articles that consider the reliability of pharmacological research publications, and approaches to their improvement in this regard. This first article explains the importance of publishing findings that confirm or repudiate published findings (so called "replication" studies). It also emphasizes that PR&P actively encourages submission of such articles, and seeks to oppose the publication bias that favors publication of "positive" findings. The second paper explores some initiatives to publish "negative" clinical findings, including a PR&P initiative. The final paper elaborates a toolkit that can be applied to drug discovery research to facilitate the reliability of findings.

摘要

药理学研究领域正在发生变化,以适应更高透明度和更好标准的需求。本文包含的专题文章解释了药理学研究与展望 (PR&P) 如何应对这一议程。本期 PR&P 包含三篇文章,探讨了药理学研究出版物的可靠性,以及改进这方面的方法。本文首先解释了发表证实或反驳已发表研究结果的发现的重要性(所谓的“重复”研究)。它还强调 PR&P 积极鼓励提交此类文章,并试图反对有利于发表“阳性”发现的发表偏倚。第二篇论文探讨了一些发表“阴性”临床发现的举措,包括 PR&P 的举措。最后一篇论文详细阐述了一个可应用于药物发现研究的工具包,以促进研究结果的可靠性。

相似文献

1
Replication - why we need to publish our findings.
Pharmacol Res Perspect. 2015 Aug;3(4):e00164. doi: 10.1002/prp2.164. Epub 2015 Jul 24.
2
Authors' Submission Toolkit: a practical guide to getting your research published.
Curr Med Res Opin. 2010 Aug;26(8):1967-82. doi: 10.1185/03007995.2010.499344.
4
The incentive to publish negative studies: how beta-blockers and depression got stuck in the publication cycle.
J Clin Epidemiol. 2012 May;65(5):488-92. doi: 10.1016/j.jclinepi.2011.06.022. Epub 2012 Feb 18.
6
Publication rates of pharmaceutical scientists: application of the waring distribution.
Drug Metab Rev. 1987;18(4):553-71. doi: 10.3109/03602538708994132.
7
Meta-analysis: Problems with Russian Publications.
Int J Risk Saf Med. 2015;27 Suppl 1:S89-90. doi: 10.3233/JRS-150702.
9
F1000Research: Tics welcomes you to 21st century biomedical publishing.
F1000Res. 2014 Nov 12;3:272. doi: 10.12688/f1000research.5664.1. eCollection 2014.

引用本文的文献

1
2
Evidence synthesis, digital scribes, and translational challenges for artificial intelligence in healthcare.
Cell Rep Med. 2022 Dec 20;3(12):100860. doi: 10.1016/j.xcrm.2022.100860. Epub 2022 Dec 12.
3
A Systematic Review of Polygenic Models for Predicting Drug Outcomes.
J Pers Med. 2022 Aug 27;12(9):1394. doi: 10.3390/jpm12091394.
4
It is easy to become an author in scientific journals now but, what are the implications?
Indian J Urol. 2021 Oct-Dec;37(4):303-306. doi: 10.4103/iju.iju_341_21.
5
Does health informatics have a replication crisis?
J Am Med Inform Assoc. 2018 Aug 1;25(8):963-968. doi: 10.1093/jamia/ocy028.
6
Helping to drive the robustness of preclinical research - the assay capability tool.
Pharmacol Res Perspect. 2015 Aug;3(4):e00162. doi: 10.1002/prp2.162. Epub 2015 Jul 24.

本文引用的文献

1
Experimental design and analysis and their reporting: new guidance for publication in BJP.
Br J Pharmacol. 2015 Jul;172(14):3461-71. doi: 10.1111/bph.12856.
4
Evaluation of excess significance bias in animal studies of neurological diseases.
PLoS Biol. 2013 Jul;11(7):e1001609. doi: 10.1371/journal.pbio.1001609. Epub 2013 Jul 16.
5
The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias.
Pharmacol Ther. 2013 Aug;139(2):213-48. doi: 10.1016/j.pharmthera.2013.04.008. Epub 2013 Apr 12.
6
Attrition in the drug discovery process: lessons to be learned from the safety pharmacology paradigm.
Expert Rev Clin Pharmacol. 2012 May;5(3):237-40. doi: 10.1586/ecp.12.22.
7
Replication studies: Bad copy.
Nature. 2012 May 16;485(7398):298-300. doi: 10.1038/485298a.
8
Reliability of 'new drug target' claims called into question.
Nat Rev Drug Discov. 2011 Aug 31;10(9):643-4. doi: 10.1038/nrd3545.
9
"Positive" results increase down the Hierarchy of the Sciences.
PLoS One. 2010 Apr 7;5(4):e10068. doi: 10.1371/journal.pone.0010068.
10
Design, power, and interpretation of studies in the standard murine model of ALS.
Amyotroph Lateral Scler. 2008;9(1):4-15. doi: 10.1080/17482960701856300.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验